GoldenGolden
Advanced Search
Catalyst Biosciences

Catalyst Biosciences

Catalyst Biosciences is a clinical development biopharmaceutical and research company.

Catalyst Biosciences is a clinical development biopharmaceutical and research company that focuses on addressing unmet medical needs in disorders of the complement and coagulation systems.

Timeline

May 18, 2021
Catalyst Biosciences announces first patient dosed in marzeptacog alfa (activated) Phase 1/2 study in Factor VII Deficiency, Glanzmann Thrombasthenia and Hemophilia A treated with Hemlibra.
January 2021
Catalyst Biosciences raises a $50,000,000 venture round.
September 22, 2015
Catalyst Biosciences was founded by Charles S. Craik, Christopher Thanos, Jack Nguyen and Sandra Waugh Ruggles.
June 2015
Catalyst Biosciences raises a $1,000,000 venture round.
February 2015
Catalyst Biosciences raises a $3,200,000 venture round.
April 2014
Catalyst Biosciences raises a $5,000,000 venture round.
August 2013
Catalyst Biosciences raises a $400,000 venture round.
April 2013
Catalyst Biosciences raises a $5,100,000 venture round from Burrill & Company, Essex Woodlands Health Ventures, HealthCare Ventures, Johnson & Johnson Development Corporation, Morgenthaler Ventures and Novartis Venture Fund.
September 2012
Catalyst Biosciences raises a $13,400,000 venture round from Burrill & Company, Essex Woodlands Health Ventures, HealthCare Ventures, Johnson & Johnson Development Corporation, Morgenthaler Ventures and Sofinnova Investments.
January 1, 2012
Catalyst Biosciences raises a $7,000,000 venture round.
Page 1 of 2

Funding rounds

People

Name
Role
LinkedIn

Brajesh Kumar

Employee

David L Sloane

Employee

Elena Kren

Employee

Jacob Esparza

Employee

Jeff Landau

Employee

Lianne Gong

Employee

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
May 18, 2021
BioSpace
Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the initiation of dosing in the Company's Phase 1/2 study (MAA-202) of marzeptacog alfa (activated) - known as "MarzAA." MarzAA is a subcutaneously (SQ) administered next-generation engineered coagulation Factor VIIa (FVIIa).
BioSpace
May 5, 2021
BioSpace
Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the dosing of the first patient in the Crimson 1 Study, the Company's Phase 3 registration trial (MAA-304 - Crimson 1) of Marzeptacog alfa (activated) - or MarzAA, the Company's subcutaneously (SQ) administered next-generation engineered recombinant coagulation Factor VIIa (rFVIIa).
BioSpace
April 19, 2021
BioSpace
Catalyst Biosciences, Inc. announced the publication of preclinical data from its study of CB 2679d-GT in Hemophilia B mice in Blood, the peer-reviewed, official journal of the American Society of Hematology.
BioSpace
December 2, 2020
BioSpace
Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for Marzeptacog alfa (activated) - or MarzAA, the Company's subcutaneously (SQ) administered next-generation engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with Hemophilia A or B with inhibitors that will enter a pivotal Phase 3 study CRIMSON 1 this m
BioSpace
June 10, 2020
BioSpace
Catalyst Biosciences, Inc. (NASDAQ: CBIO), a biopharmaceutical company developing novel subcutaneous (SQ) therapies for hemophilia and other bleeding disorders, today announced completion of its Phase 1 MAA-102 study for Marzeptacog alfa (activated) (MarzAA). The results support the use of SQ MarzAA to treat episodic bleeding. The company is on track to enroll the first patient in its Phase 3 registration trial evaluating the effic

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.